Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Combo Therapy More Effective in Removing Beta-Amyloid from Mice Brains

July 14, 2014 2:19 pm | News | Comments

Eli Lilly and Co. announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE. Read more...      

TOPICS:

Janssen Pharmaceuticals Seeks Expanded Label for Invega Sustenna

July 14, 2014 2:14 pm | News | Comments

Janssen Pharmaceuticals announced the submission of a supplemental New Drug Application to the FDA seeking a label change that, if approved, would include new data showing significantly delayed time to relapse in patients prescribed once-monthly atypical long-acting antipsychotic Invega Sustenna. Read more...

TOPICS:

Antibody Halts Cancer-Related Wasting Condition

July 14, 2014 2:05 pm | News | Comments

New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle that occurs in about half of all cancer patients, raising their risk of death. Read more...             

TOPICS:
Advertisement

Senators Seek Details on Gilead's Solvaldi Pricing

July 14, 2014 1:53 pm | News | Comments

Senate Finance Committee Chairman Ron Wyden, D-Ore., and senior Finance Committee member Chuck Grassley, R-Iowa, are requestinh detailed pricing information on the costly new Hepatitis C virus (HCV) drug Solvaldi. Read more...        

TOPICS:

New Technology Delivers Cargo, Doesn’t Disrupt Cell

July 14, 2014 10:59 am | News | Comments

Portage Biotech announced that Portage Pharmaceuticals has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes that delivers an active pharmacological agent or cargo into a cell without disrupting the cell membrane. Read more...

TOPICS:

Mylan to Buy Abbott Generic-Drugs Business for $5.3B

July 14, 2014 10:50 am | News | Comments

The generic drugmaker Mylan is buying Abbott Laboratories' generic-drugs business in developed markets for stock valued at about $5.3 billion in a deal that will diversify and expand its business outside the U.S. when the combined company is organized in the Netherlands. Read more...

TOPICS:

Oral Drug Improves Vision in Patients with Inherited Blindness

July 14, 2014 10:43 am | News | Comments

An international research project, led by the Research Institute of the McGill University Health Centre in Montreal, reported that a new oral medication is showing significant progress in restoring vision to patients with Leber congenital amaurosis (LCA). Read more...

TOPICS:

Melanoma Drug Combo Meets Primary Endpoint

July 14, 2014 10:34 am | News | Comments

Roche announced that the Phase 3 coBRIM study met its primary endpoint when it demonstrated that cobimetinib, used in combination with Zelboraf, helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer without their disease worsening compared to Zelboraf alone. Read more...

TOPICS:
Advertisement

China Indicts U.S., British Investigators

July 14, 2014 10:28 am | by Gillian Wong, Associated Press | News | Comments

Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him. Read more...

TOPICS:

Ebola Crisis Deepens, 500+ Dead

July 14, 2014 10:22 am | by Krista Larson, Associated Press | News | Comments

Deep in the forests of southern Guinea, the first victims fell ill with high fevers. People assumed it was the perennial killer malaria and had no reason to fear touching the bodies, as is the custom in traditional funerals, and unknowingly spread what ultimately was discovered to be Ebola. Read more...

TOPICS:

AbbVie, Shire Enter Detailed Combination Talks

July 14, 2014 7:23 am | by Tom Murphy, AP Business Writer | News | Comments

Drugmakers AbbVie and Shire have entered detailed talks about a possible combination after AbbVie raised its bid once again and offered to give Shire shareholders a bigger stake in the resulting company. Read more...          

TOPICS:

Significant Increase in Antibiotic Use Across the World, Study Shows

July 11, 2014 3:23 pm | News | Comments

Global use of antibiotics is surging, according to researchers who have conducted a broad assessment of antibiotic consumption around the world. Read more...                            

TOPICS:

Ipsen, Galderma Expand Neurotoxin Partnership

July 11, 2014 3:16 pm | News | Comments

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, announced that they have significantly expanded the scope of their neurotoxin partnership. Read more...   

TOPICS:

New Compound Treats Blindness, Diabetes in Mice

July 11, 2014 3:03 pm | News | Comments

In a new study, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. Read more...      

TOPICS:

Girl Hoped to Have Been Cured of HIV Has Relapsed

July 11, 2014 2:51 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

A Mississippi girl born with the AIDS virus and in remission for more than two years despite stopping treatment now shows signs that she still harbors HIV- and therefore is not cured. Read more...                

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading